BAY 383045Alternative Names: PDE 1/5 inhibitor - Bayer; PDE I/V inhibitor - Bayer; Phosphodiesterase I/V inhibitor - Bayer
Latest Information Update: 09 Jul 2002
At a glance
- Originator Bayer
- Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Angina pectoris; Myocardial infarction
Most Recent Events
- 10 May 1999 New profile
- 10 May 1999 Preclinical development for Angina pectoris in Germany (Unknown route)
- 10 May 1999 Preclinical development for Myocardial infarction in Germany (Unknown route)